Adaptation of vectors and drug‐inducible systems for controlled expression of transgenes in the tumor microenvironment

[1]  J. Cochran,et al.  Targeting ligand-receptor interactions for development of cancer therapeutics. , 2017, Current opinion in chemical biology.

[2]  M. Kiehl,et al.  New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management , 2017, Critical Care.

[3]  R. Alemany,et al.  Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic delivery. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[4]  Mads Kærn,et al.  Improvement of the reverse tetracycline transactivator by single amino acid substitutions that reduce leaky target gene expression to undetectable levels , 2016, Scientific Reports.

[5]  M. Valsecchi.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[6]  I. Melero,et al.  Evolving synergistic combinations of targeted immunotherapies to combat cancer , 2015, Nature Reviews Cancer.

[7]  N. Lemoine,et al.  New role of Interleukin-10 in enhancing the antitumor efficacy of oncolytic vaccinia virus for treatment of pancreatic cancer , 2015, Oncoimmunology.

[8]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[9]  M. Buñuales,et al.  Safety and antitumor effect of oncolytic and helper-dependent adenoviruses expressing interleukin-12 variants in a hamster pancreatic cancer model , 2015, Gene Therapy.

[10]  M. Ychou,et al.  Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies. , 2014, Cancer treatment reviews.

[11]  A. Beaudet,et al.  Transgene expression up to 7 years in nonhuman primates following hepatic transduction with helper-dependent adenoviral vectors. , 2013, Human gene therapy.

[12]  S. Kügler,et al.  Adeno-associated Virus-mediated, Mifepristone-regulated Transgene Expression in the Brain , 2013, Molecular therapy. Nucleic acids.

[13]  J. Prieto,et al.  Cytokines for the treatment of gastrointestinal cancers: clinical experience and new perspectives , 2013, Expert opinion on investigational drugs.

[14]  J. Nalbantoglu,et al.  Strength and muscle specificity of a compact promoter derived from the slow troponin I gene in the context of episomal (gutless adenovirus) and integrating (lentiviral) vectors , 2012, The journal of gene medicine.

[15]  R. Mandel,et al.  Regulated protein expression for in vivo gene therapy for neurological disorders: Progress, strategies, and issues , 2012, Neurobiology of Disease.

[16]  A. Hoffman,et al.  Successful long-term treatment of Cushing disease with mifepristone (RU486). , 2012, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[17]  J. Prieto,et al.  Self-inactivating helper virus for the production of high-capacity adenoviral vectors , 2011, Gene Therapy.

[18]  P. Ng,et al.  Helper-Dependent Adenoviral Vectors. , 2011, Journal of genetic syndromes & gene therapy.

[19]  J. Prieto,et al.  Development of a liver-specific Tet-on inducible system for AAV vectors and its application in the treatment of liver cancer. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  J. Prieto,et al.  Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice , 2010, Gut.

[21]  B Sangro,et al.  A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma , 2010, Cancer Gene Therapy.

[22]  D. Curiel,et al.  A conditionally replicative adenovirus, CRAd-S-pK7, can target endometriosis with a cell-killing effect. , 2010, Human reproduction.

[23]  A. Ehrhardt,et al.  Persistence of high-capacity adenoviral vectors as replication-defective monomeric genomes in vitro and in murine liver. , 2009, Human gene therapy.

[24]  C. Ortiz de Solórzano,et al.  Evaluation of bioluminescent imaging for noninvasive monitoring of colorectal cancer progression in the liver and its response to immunogene therapy , 2009, Molecular Cancer.

[25]  J. Rivas,et al.  Interleukin-12 inhibits liver-specific drug-inducible systems in vivo , 2008, Gene Therapy.

[26]  C. Barcia,et al.  One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[27]  Su-Chun Zhang,et al.  Transgenes delivered by lentiviral vector are suppressed in human embryonic stem cells in a promoter-dependent manner. , 2007, Stem cells and development.

[28]  C. Ge,et al.  Use of a stringent dimerizer-regulated gene expression system for controlled BMP2 delivery. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[29]  A. Rivera,et al.  Strategies to enhance transductional efficiency of adenoviral‐based gene transfer to primary human fibroblasts and keratinocytes as a platform in dermal wounds , 2006, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[30]  C. Russell,et al.  Long-Term Administration of Mifepristone (RU486): Clinical Tolerance During Extended Treatment of Meningioma , 2006, Cancer investigation.

[31]  J. Prieto,et al.  IFN-alpha gene therapy for woodchuck hepatitis with adeno-associated virus: differences in duration of gene expression and antiviral activity using intraportal or intramuscular routes. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  J. Barrio,et al.  Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. , 2005, Gastroenterology.

[33]  J. Prieto,et al.  Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  C. Marth,et al.  Why did p53 gene therapy fail in ovarian cancer? , 2003, The Lancet. Oncology.

[35]  T. Mayumi,et al.  Regulated gene expression from adenovirus vectors: a systematic comparison of various inducible systems. , 2003, Gene.

[36]  D. Bohl,et al.  Lack of an Immune Response against the Tetracycline-Dependent Transactivator Correlates with Long-Term Doxycycline-Regulated Transgene Expression in Nonhuman Primates after Intramuscular Injection of Recombinant Adeno-Associated Virus , 2002, Journal of Virology.

[37]  A. Mahfoudi,et al.  Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgene expression. , 2002, Human gene therapy.

[38]  A. Beaudet,et al.  Generation of helper-dependent adenoviral vectors by homologous recombination. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[39]  B. Byrne,et al.  CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. , 2001, Human gene therapy.

[40]  J. Perrard,et al.  Ligand-dependent regulation of vascular endothelial growth factor and erythropoietin expression by a plasmid-based autoinducible GeneSwitch system. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[41]  J. Prieto,et al.  Intratumoral Coinjection of Two Adenoviruses, One Encoding the Chemokine IFN-γ-Inducible Protein-10 and Another Encoding IL-12, Results in Marked Antitumoral Synergy1 , 2000, The Journal of Immunology.

[42]  B. O’Malley,et al.  Adenovirus-mediated regulable target gene expression in vivo. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[43]  A. Sagalowsky,et al.  Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. , 1999, Cancer research.

[44]  C. Miller,et al.  Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. , 1998, Cancer Research.

[45]  C. Miller,et al.  An Adenovirus Vector with Genetically Modified Fibers Demonstrates Expanded Tropism via Utilization of a Coxsackievirus and Adenovirus Receptor-Independent Cell Entry Mechanism , 1998, Journal of Virology.

[46]  J. Leonard,et al.  Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12–Associated Toxicity and Interferon-γ Production , 1997 .

[47]  D. Brough,et al.  Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types , 1996, Nature Biotechnology.

[48]  P. Sharp,et al.  Structure-based design of transcription factors. , 1995, Science.

[49]  H. Ertl,et al.  MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. , 1994, Immunity.

[50]  Paul Tempst,et al.  RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs , 1994, Cell.

[51]  Yamamura Ken-ichi,et al.  Efficient selection for high-expression transfectants with a novel eukaryotic vector , 1991 .

[52]  H. Niwa,et al.  Efficient selection for high-expression transfectants with a novel eukaryotic vector. , 1991, Gene.

[53]  M. Peipp,et al.  Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions. , 2014, Methods.

[54]  R. Crystal.  Adenovirus: the first effective in vivo gene delivery vector. , 2014, Human gene therapy.

[55]  Zinnia P. Parra-Guillen,et al.  Target-Mediated Disposition Model Describing the Dynamics of IL12 and IFNγ after Administration of a Mifepristone-Inducible Adenoviral Vector for IL-12 Expression in Mice , 2012, The AAPS Journal.

[56]  S. Kochanek,et al.  Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[57]  Brendan H. Lee,et al.  Large-scale production of high-quality helper-dependent adenoviral vectors using adherent cells in cell factories. , 2010, Human gene therapy.

[58]  J. Prieto,et al.  Prolonged and inducible transgene expression in the liver using gutless adenovirus: a potential therapy for liver cancer. , 2004, Gastroenterology.

[59]  高野昌平,et al.  悪性グリオーマに対するconditionally replicative adenovirusを用いた遺伝子治療 , 2004 .

[60]  A. Beaudet,et al.  Helper-dependent adenoviral vectors. , 2002, Methods in enzymology.

[61]  J. Leonard,et al.  Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. , 1997, Blood.